BRIEF-Versartis reports new data on Somavaratan in growth hormone deficiency
April 3 Versartis Inc
* Versartis reports new data on long-acting Somavaratan in growth hormone deficiency at endo 2017
* Baseline characteristics of phase 3 velocity trial population balanced between study arms and comparable to phase 2
* Further results from vital trial in adult ghd-similar Somavaratan PK/PD data in U.S., Japanese children support using same dose in ongoing phase 3 trials Source text for Eikon: Further company coverage: